Versant Ventures et al. back VectivBio

The company will use the fresh capital from the international group of life-sciences-focused investors to launch, following its spin-out from Basel-based Therachon in 2019.

Therachon's former chief executive officer, chief financial officer, chief medical officer and chief business officer will join the management team of VectivBio as part of the launch. Tom Woiwode of Versant will also join the company's board.

Versant is currently deploying from vehicles including Versant Venture Capital II, which held a final close in December 2018 on its hard-cap of $600m. The fund focuses on biotechnology companies in the US, Canada and western Europe, and plans to invest in 20 or more businesses.

Copenhagen-based Novo Holdings is wholly owned by Novo Nordisk. The firm focuses on life sciences investments.

Company
VectivBio develops clinical-stage biotechnology therapies for patients with serious and rare conditions such as short-bowel syndrome, which affects approximately 35,000 people in the US and Europe.

The company was formed as a spin-out from Therachon, which was acquired by Pfizer in 2018 for up to $810m. It is based in Basel and has a headcount of 14, according to its website.

People
VectivBio – Luca Santarelli (CEO).
Versant Ventures – Tom Woiwode (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland
• BPI France